Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (hac) vs. cisplatin, adriamycin, cyclophosphamide (pac) in advanced ovarian cancer: long-term results
- 1 March 1991
- journal article
- clinical trial
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 18, 37-46
- https://doi.org/10.1016/0305-7372(91)90023-s
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.Journal of Clinical Oncology, 1989
- Controversy over combination chemotherapy in advanced ovarian cancer: what we learn from reports of matured data.Journal of Clinical Oncology, 1986
- Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trialCancer Chemotherapy and Pharmacology, 1985
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958